Inovio Pharmaceuticals Inc

Sumner Michael John’s latest insider trade shows cautious confidence in Inovio amid a pending lawsuit, revealing a long‑term buy‑sell strategy for investors to weigh.

Inovio insider buying signals confidence in its DNA vaccine pipeline, sparking optimism for future clinical milestones and potential upside despite current undervaluation.

Inovio insider moves reveal a liquidity‑focused strategy: chief scientific officer Humeau Laurent buys and sells RSUs, hinting at short‑term cash needs while still backing the company’s vaccine pipeline.